Impact of Alcohol Use Disorder Treatment on Clinical Outcomes among Patients with Cirrhosis

Hepatology

A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder

Hepatology.

Bajaj JS, Gavis EA, Fagan A, Wade JB, Thacker LR, Fuchs M, Patel S, Davis B, Meador J, Puri P, Sikaroodi M, Gillevet PM

doi: 10.1002/hep.31496.

Hepatology

Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Non-alcoholic Steatohepatitis-related, Child-Pugh A Cirrhosis

Clin Gastroenterol Hepatol.

Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Eslam M, Lai-Hung Wong G, George J, Romero-Gomez M, Adams LA

doi: 10.1016/j.cgh.2020.04.083.

Hepatology

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Adv Ther.

Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, Bondin M, Zhang Z, Marra F, Belperio PS, Wedemeyer H, Flamm S

doi: 10.1007/s12325-020-01449-0.

Irritable Bowel Syndrome (IBS) and Chronic Constipation

The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea

Qual Life Res.

Abel JL, Carson RT, Andrae DA

doi: 10.1007/s11136-018-2008-z.

HepatitisHepatology

ACG Clinical Guideline: Alcoholic Liver Disease

Am J Gastroenterol.

Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH

doi: 10.1038/ajg.2017.469.

Hepatology

Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation

J Hepatol.

Giannelli V, Roux O, Laouénan C, Manchon P, Ausloos F, Bachelet D, Rautou PE, Weiss E, Moreau R, Mebazaa A, Cohen-Solal A, Durand F, Francoz C

doi: 10.1016/j.jhep.2019.10.002.

Inflammatory Bowel Disease

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

Clin Gastroenterol Hepatol.

Dulai PS, Singh S, Casteele NV, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV Jr, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C

doi: 10.1016/j.cgh.2020.02.010.

Gastrointestinal Diseases

Opioid Use and Potency are Associated with Clinical Features, Quality of Life, and Use of Resources in Patients with Gastroparesis

Clin Gastroenterol Hepatol.

Hasler WL, Wilson LA, Nguyen LA, Snape WJ, Abell TL, Koch KL, McCallum RW, Pasricha PJ, Sarosiek I, Farrugia G, Grover M, Lee LA, Miriel L, Tonascia J, Hamilton FA, Parkman HP, Gastroparesis Clinical Research Consortium (GpCRC)

doi: 10.1016/j.cgh.

Hepatology

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

J Gastroenterol Hepatol.

Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T

doi: 10.1111/jgh.15172.

Related content

A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder

Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Non-alcoholic Steatohepatitis-related, Child-Pugh A Cirrhosis

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea

ACG Clinical Guideline: Alcoholic Liver Disease

Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

Opioid Use and Potency are Associated with Clinical Features, Quality of Life, and Use of Resources in Patients with Gastroparesis

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH